Program
MH004
A development code. Also written as “MH004 1.0% Ointment”, “MH004 Ointment” and “MH004 0.1% Ointment”.
Its studies are mostly in Dermatitis, Atopic · Vitiligo, led by Minghui Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Minghui Pharmaceutical | 51 open or running | phase 3since Sep 12, 2025 | Mar 19, 2021 | Feb 23, 2028phase 3 · NCT07682506 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 19, 2021First study: phase 1 study in Dermatitis, AtopicFirst studyNCT04815148 · 72 enrolled
- Sep 12, 2025Phase 3 study in Dermatitis, AtopicNCT07185282 · 375 enrolled · China
- Sep 12, 20252 phase 2 studiesNCT07182864, NCT07181187
- Jun 28, 2026Phase 3 study in VitiligoNCT07682506 · 405 planned · China
Ahead
- Feb 23, 2028Primary completion: phase 3 study in VitiligoNCT07682506
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07682506Vitiligo · China | 3 | Recruiting | Feb 23, 2028 | 405 |
| NCT07185282Dermatitis, Atopic · China | 3 | Completed | Dec 13, 2024 | 375 |
| NCT07182864Dermatitis, Atopic · China | 2 | Completed | Sep 8, 2022 | 160 |
| NCT07181187Vitiligo · China | 2 | Completed | Sep 24, 2025 | 156 |
| NCT04815148Dermatitis, Atopic | 1 | UNKNOWN | Mar 31, 2022 | 72 |
How it is read
Names in the registry
- “MH004 1.0% Ointment”, 2 entries
- “MH004 Ointment”, 2 entries
- “MH004 0.1% Ointment”, 1 entry
- “MH004 0.3% Ointment”, 1 entry
- “MH004 3.0% Ointment”, 1 entry
Codes read as this program: MH004.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 3 studies
- Vitiligo, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.